These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15942883)

  • 1. Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.
    Anon JB
    Clin Infect Dis; 2005 Jul; 41 Suppl 2(Suppl 2):S167-76. PubMed ID: 15942883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.
    Anon JB; Jacobs MR; Poole MD; Ambrose PG; Benninger MS; Hadley JA; Craig WA;
    Otolaryngol Head Neck Surg; 2004 Jan; 130(1 Suppl):1-45. PubMed ID: 14726904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [15-year experience of moxifloxacin in the treatment of patients with bacterial rhinosinusitis].
    Ovchinnikov AY; Edzhe MA; Miroshnichenko NA; Hon EM; Korostelev SA
    Vestn Otorinolaringol; 2015; 80(3):75-79. PubMed ID: 26331163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of rhinosinusitis in the outpatient setting.
    Poole MD; Portugal LG
    Am J Med; 2005 Jul; 118 Suppl 7A():45S-50S. PubMed ID: 15993677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of patients receiving moxifloxacin for acute bacterial rhinosinusitis in clinical practice: results from an international, observational cohort study.
    Mösges R; Desrosiers M; Arvis P; Heldner S
    PLoS One; 2013; 8(4):e61927. PubMed ID: 23626752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute bacterial rhinosinusitis in pediatric medicine: current issues in diagnosis and management.
    Anon JB
    Paediatr Drugs; 2003; 5 Suppl 1():25-33. PubMed ID: 14632103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.
    Karageorgopoulos DE; Giannopoulou KP; Grammatikos AP; Dimopoulos G; Falagas ME
    CMAJ; 2008 Mar; 178(7):845-54. PubMed ID: 18362380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of fluoroquinolones against common respiratory pathogens.
    Aydemir S; Tunger A; Cilli F
    West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhinosinusitis. An overview of current management measures in acute and chronic infection.
    Hadley JA
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):30-6. PubMed ID: 19667547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
    Keating KN; Friedman HS; Perfetto EM
    Curr Med Res Opin; 2006 Feb; 22(2):327-33. PubMed ID: 16466604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
    Sher LD; Poole MD; Von Seggern K; Wikler MA; Nicholson SC; Pankey GA
    Otolaryngol Head Neck Surg; 2002 Sep; 127(3):182-9. PubMed ID: 12297808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute bacterial rhinosinusitis in adults: part II. Treatment.
    Scheid DC; Hamm RM
    Am Fam Physician; 2004 Nov; 70(9):1697-704. PubMed ID: 15554487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
    Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone.
    Drago L; Mattina R; Legnani D; Romano CL; Vianello E; Ricci C; De Vecchi E
    Int J Immunopathol Pharmacol; 2011; 24(4):1027-35. PubMed ID: 22230408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of fluoroquinolones against pathogenic oral bacteria.
    Núñez Otero V; Limeres Posse J; Carmona IT; Diz Dios P
    Mini Rev Med Chem; 2009 Sep; 9(10):1147-58. PubMed ID: 19534690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of moxifloxacin in the treatment of acute bacterial sinusitis caused by penicillin-resistant Streptococcus pneumoniae: a pooled analysis.
    Johnson P; Cihon C; Herrington J; Choudhri S
    Clin Ther; 2004 Feb; 26(2):224-31. PubMed ID: 15038945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute bacterial rhinosinusitis: clinical impact of resistance and susceptibility.
    Poole MD
    Am J Med; 2004 Aug; 117 Suppl 3A():29S-38S. PubMed ID: 15360095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
    Hoepelman I
    Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.